Structural optimization of pyrrolopyrimidine BTK inhibitors based on molecular simulation

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Drug Discovery

Background:

• Bruton's tyrosine kinase (BTK) is crucial for B-cell development and implicated in various diseases like tumors and leukemia.
• BTK inhibitors offer therapeutic potential for treating B-cell malignancies and autoimmune disorders.
• Developing novel, potent, and selective BTK inhibitors remains a key area in drug discovery.

Purpose of the Study:

• To design and identify novel BTK inhibitors with enhanced inhibitory activity and favorable drug-like properties.
• To explore the structure-activity relationships of pyrrolopyrimidine derivatives as BTK inhibitors.
• To provide a computational basis for the rational design of next-generation BTK-targeted therapeutics.

Main Methods:

• Quantitative Structure-Activity Relationship (3D-QSAR) modeling, including Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA), was employed.
• Molecular docking simulations were performed to assess binding affinities of designed inhibitors with BTK.
• Molecular dynamics (MD) simulations and binding free energy calculations were utilized to validate docking results and analyze inhibitor-protein interactions.

Main Results:

• A robust 3D-QSAR model (CoMFA: q²=0.519, R²=0.971; CoMSIA: q²=0.512, R²=0.990) was established, demonstrating excellent predictive power.
• Eight novel pyrrolopyrimidine derivatives were designed, exhibiting higher predicted inhibitory activities and binding affinities to BTK compared to the template.
• MD simulations confirmed the crucial role of specific amino acid residues (Leu528, Val416, Met477) in BTK inhibition and indicated enhanced binding stability of novel compounds.
• Predicted ADME/T properties suggested favorable pharmacokinetic profiles for the majority of the designed molecules.

Conclusions:

• The developed 3D-QSAR models provide a reliable framework for designing potent BTK inhibitors.
• The novel designed molecules represent promising candidates for further preclinical development as BTK-targeted agents.
• This study underscores the efficacy of integrated computational approaches in accelerating the discovery of novel therapeutics.